Search the Blog
Second Tier Newborn Screening Tests – Improving the Specificity of One of the Greatest Public Health Achievements
Newborn screening for inherited disorders has been heralded as one of the 10 greatest public health achievements of the first decade of the 21st century.1 The ability to pre-symptomatically identify newborn babies at risk of developing endocrine, hematologic, and metabolic disorders has dramatically improved or saved thousands of lives (and saved the healthcare system millions...
Method Lifecycle Management Survey Reveals Barriers and Enthusiasm for Change
Waters recently surveyed 100 method developers from innovator and generic pharmaceutical companies to better understand their existing challenges and views on Method Lifecycle Management (MLCM). We'll share with you the top questions and findings from our survey results.
Data Integrity Matters | Limiting Access to Tools That Could Be used to Manipulate Data (Part 3)
How do data integration and reintegration affect data integrity?
Enhancing Analytical Productivity by Breaking Down Silos – Part 3
Analytical data can be so much more than a historical point in time documented in a single report. In fact, biopharmaceutical organizations can use LC-MS data to build a continuum of compliance.
Future-Proofing Pharmaceutical R&D to Accelerate Aerosol Science Innovation
At Chiesi Group’s Chippenham laboratory in the UK, Waters’ UPLC systems with mass detection and informatics keep the team at the forefront of inhalation drug delivery products.
Automating Metabolic Flux Analysis Workflows in Cancer Research
We perform a study using Symphony Data Pipeline software in combination with Elucidata's MSConvert and EIMaven to automate data processing in the comparison of 2D and 3D in vitro cultures in non-small-cell lung carcinoma.
National Newborn Screening Programs: An Overview of Challenges and Successes
Don Mason reviews the state of newborn screening (NBS) programs around the world.
How Mass Detection Helps a CRO in China Expand its Outsourced Drug Discovery Services
Learn how the ACQUITY QDa Mass Detector brings the power of mass detection for purification to Medicilon, helping this CRO meet the growing demand for outsourced services in the pharmaceutical and biotechnology industries.